Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus platinum-based chemotherapy versus pembrolizumab alone in first-line PD-L1-high NSCLC
2020-002626-86Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Jun 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, carboplatin, cisplatin, paclitaxel and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: Progression-free survival. Started Jun 2020; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-002626-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002626-86.